HSD17B13
17-beta-hydroxysteroid dehydrogenase 13
Also known as: DHB13_HUMAN, SCDR9, SDR16C3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7Z5P4
- Gene
- HSD17B13
- Ensembl
- ENSG00000170509
- Chromosome
- 4
- Canonical length
- 300 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Golgi apparatus,Vesicles
OverviewNCBI Gene
Predicted to enable oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor and steroid dehydrogenase activity. Acts upstream of or within positive regulation of lipid biosynthetic process. Located in lipid droplet. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
300 residues, UniProt reviewed canonical sequence.
>Q7Z5P4|HSD17B13
1 MNIILEILLL LITIIYSYLE SLVKFFIPQR RKSVAGEIVL ITGAGHGIGR QTTYEFAKRQ
61 SILVLWDINK RGVEETAAEC RKLGVTAHAY VVDCSNREEI YRSLNQVKKE VGDVTIVVNN
121 AGTVYPADLL STKDEEITKT FEVNILGHFW ITKALLPSMM ERNHGHIVTV ASVCGHEGIP
181 YLIPYCSSKF AAVGFHRGLT SELQALGKTG IKTSCLCPVF VNTGFTKNPS TRLWPVLETD
241 EVVRSLIDGI LTNKKMIFVP SYINIFLRLQ KFLPERASAI LNRMQNIQFE AVVGHKIKMKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against HSD17B13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 536 nTPM
Expression across tissuesHPA
Tissue
- liver: 536 nTPM
- adipose tissue: 8.8 nTPM
- vagina: 7.2 nTPM
- breast: 6.1 nTPM
- skin: 6.1 nTPM
- prostate: 4.3 nTPM
Single-cell type
- hepatocytes: 177 nCPM
- transitional alveolar cells: 73 nCPM
- prostatic club cells: 68 nCPM
- basal prostatic cells: 42 nCPM
- respiratory ciliated cells: 28 nCPM
- prostatic hillock cells: 19 nCPM
Immune cell
- basophil: 0.7 nTPM
- memory B-cell: 0.6 nTPM
- neutrophil: 0.6 nTPM
- eosinophil: 0.4 nTPM
- naive B-cell: 0.2 nTPM
- classical monocyte: 0.1 nTPM
Brain region
- cerebellum: 7.4 nTPM
- cerebral cortex: 4.3 nTPM
- pons: 4.2 nTPM
- white matter: 3.9 nTPM
- medulla oblongata: 3.8 nTPM
- amygdala: 3.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.14
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.02
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- all-trans-retinol dehydrogenase (NAD+) activity
- estradiol 17-beta-dehydrogenase [NAD(P)+] activity
- oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
- steroid dehydrogenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads HSD17B13 as an antibody target. Whether an autoantibody or antibody against HSD17B13 could matter depends on whether native HSD17B13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
HSD17B13 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label HSD17B13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...